Annual Net Sales outside of the United States. In further consideration of the licenses and other rights granted to Neurocrine with respect to each Discovery Program, Neurocrine shall make tiered royalty payments to Voyager in respect of Annual Net Sales in the Territory outside the United States, on a Collaboration Product-by-Collaboration Product basis, of Collaboration Products under each Discovery Program. Annual Net Sales outside the United States of the Collaboration Product Tiered Royalty Rate
Appears in 2 contracts
Samples: Stock Purchase Agreement (Voyager Therapeutics, Inc.), Stock Purchase Agreement (Neurocrine Biosciences Inc)
Annual Net Sales outside of the United States. In further consideration of for the licenses and other rights granted to Neurocrine with respect to each Discovery the AADC Program, Neurocrine shall make tiered royalty payments to Voyager in respect of Annual Net Sales in the Territory outside the United States, on a Collaboration Product-by-Collaboration Product basis, of Collaboration Products under each Discovery the AADC Program. Annual Net Sales outside the United States of the Collaboration Product Tiered Royalty Rate
Appears in 2 contracts
Samples: Stock Purchase Agreement (Voyager Therapeutics, Inc.), Stock Purchase Agreement (Neurocrine Biosciences Inc)
Annual Net Sales outside of the United States. In further consideration of the licenses and other rights granted to Neurocrine with respect to each Discovery the FA Program, Neurocrine shall make tiered royalty payments to Voyager in respect of Annual Net Sales in the Territory outside the United States, on a Collaboration Product-by-Collaboration Product basis, of Collaboration Products under each Discovery the FA Program. Such royalty payments shall become payable only if the Territory expands to include countries outside the United States with respect to the FA Program. Annual Net Sales outside the United States of the Collaboration Product Tiered Royalty Rate
Appears in 1 contract
Samples: Stock Purchase Agreement (Neurocrine Biosciences Inc)
Annual Net Sales outside of the United States. In further consideration of the licenses and other rights granted to Neurocrine with respect to each Discovery the FA 50 Program, Neurocrine shall make tiered royalty payments to Voyager in respect of Annual Net Sales in the Territory outside the United States, on a Collaboration Product-by-Collaboration Product basis, of Collaboration Products under each Discovery the FA Program. Such royalty payments shall become payable only if the Territory expands to include countries outside the United States with respect to the FA Program. Annual Net Sales outside the United States of the Collaboration Product Tiered Royalty Rate
Appears in 1 contract
Samples: Stock Purchase Agreement (Voyager Therapeutics, Inc.)
Annual Net Sales outside of the United States. In further consideration of for the licenses and other rights granted to Neurocrine with respect to each Discovery the GBA1 Program, Neurocrine shall make tiered royalty payments to Voyager in respect of Annual Net Sales in the Territory outside the United States, on a Collaboration Product-by-Collaboration Product basis, of Collaboration Products under each Discovery the GBA1 Program. Annual Annual Net Sales outside the United States of the Collaboration Product Tiered ProductTiered Royalty Rate
Appears in 1 contract
Samples: Collaboration and License Agreement (Voyager Therapeutics, Inc.)
Annual Net Sales outside of the United States. In further consideration of the licenses and other rights granted to Neurocrine with respect to each New Discovery Program, Neurocrine shall make tiered royalty payments to Voyager in respect of Annual Net Sales in the Territory outside the United States, on a Collaboration Product-by-Collaboration Product basis, of Collaboration Products under each New Discovery Program. Annual Annual Net Sales outside the United States of the Collaboration Product Tiered ProductTiered Royalty Rate
Appears in 1 contract
Samples: Collaboration and License Agreement (Voyager Therapeutics, Inc.)